Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/25957
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSüzer, Öner-
dc.contributor.authorYaçın, Murat-
dc.date.accessioned2022-04-21T10:56:48Z-
dc.date.available2022-04-21T10:56:48Z-
dc.date.issued2008-04-14-
dc.identifier.citationYılmaz, M.S. vd. (2008). ''Hypotensive effects of intravenously administered uridine and cytidine in conscious rats: Involvement of adenosine receptors". European Journal of Pharmacology, 584(1), 125-136.en_US
dc.identifier.issn0014-2999-
dc.identifier.issn1879-0712-
dc.identifier.urihttps://doi.org/10.1016/j.ejphar.2008.01.044-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0014299908001301-
dc.identifier.urihttp://hdl.handle.net/11452/25957-
dc.description.abstractIn the present study, we investigated the cardiovascular effects of intravenously injected uridine or cytidine, and the role of adenosine receptors in mediating these effects, in conscious normotensive rats. Intravenous (i.v.) administration of uridine (124, 250, 500 mg/kg) dose-dependently decreased arterial pressure and heart rate. Cytidine (124, 250, 500 mg/kg; i.v.) produced slight dose-related hypotension without changing heart rate. Plasma uridine and cytidine concentrations increased time- and dose-dependently while plasma adenosine levels did not change after injection of the respective nucleosides. Pretreatment with intravenous caffeine (20 mg/kg), 8-phenyltheophylline (8-PT) (I mg/kg), nonselective adenosine receptor antagonists, or 8-p-sulfophenyltheophyl line (8-SPT) (20 mg/kg), a nonselective adenosine receptor antagonist which does not cross the blood-brain barrier, abolished the cardiovascular effects of uridine (250 mg/kg; i.v.) or cytidine (250 mg/kg; i.v.). Intracerebroventricular (i.c.v.) caffeine (200 mu g) or 8-SPT (50 lug) pretreatment did not change the magnitude of the cardiovascular responses induced by nucleosides. Intravenous 8-cyclopenthyl-1,3-dipropylxanthine (DPCPX) (5 mg/kg), a selective adenosine A, receptor antagonist, greatly attenuated the cardiovascular responses to uridine and cytidine. Pretreatment with 3,7,-dimethyl-1-propargylxanthine (DMPX) (2 mg/kg), an adenosine A(1)/A(2) receptor antagonist, attenuated hypotension induced by uridine and blocked the arterial pressure decrease in response to cytidine. Uridine-induced bradycardia was blocked by DMPX. 4-(2-[7-amino-2-(2-furyl[1,2,4]-triazolo[2,3-a[1,3,5]triazin-5-yl-aminoethyl)phenol (ZM241385) (1 mg/kg; i.v.), a selective adenosine A(2A) receptor antagonist, pretreatment produced an only very small blockade in the first minute of the hypotensive effects of uridine without affecting the bradycardia. ZM241385 pretreatment completely blocked cytidine's hypotensive effect. In Langendorff-perfused rat heart preparation, uridine (10(-3) M), but not cytidine, decreased the heart rate. Our results show that intravenously injected uridnme or cytidine is able to decrease arterial pressure by activating peripheral adenosine receptors. The data also implicates that the mainly adenosine A(1) receptor activation is involved in the uridine-induced cardiovascular effects, while both adenosine A(1) and A(2A) receptor activations mediate the cytidine's effects.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectA1 receptoren_US
dc.subjectA2A receptoren_US
dc.subjectAdenosineen_US
dc.subjectCardiovascularen_US
dc.subjectCytidineen_US
dc.subjectPurinergicen_US
dc.subjectUridineen_US
dc.subjectInjected cdp-cholineen_US
dc.subjectBlood-pressureen_US
dc.subjectNitric-oxideen_US
dc.subjectA(1)en_US
dc.subjectPharmacologyen_US
dc.subjectMechanismsen_US
dc.subjectPharmacology & pharmacyen_US
dc.subject.meshAdenosineen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntihypertensive agentsen_US
dc.subject.meshBlood pressureen_US
dc.subject.meshCaffeineen_US
dc.subject.meshCarotid arteriesen_US
dc.subject.meshConsciousnessen_US
dc.subject.meshCytidineen_US
dc.subject.meshDose-response relationship, drugen_US
dc.subject.meshHeart rateen_US
dc.subject.meshHypotensionen_US
dc.subject.meshInjections, intravenousen_US
dc.subject.meshInjections, intraventricularen_US
dc.subject.meshMaleen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, wistaren_US
dc.subject.meshReceptor, adenosine a1en_US
dc.subject.meshReceptor, adenosine a2aen_US
dc.subject.meshTheobromineen_US
dc.subject.meshTheophyllineen_US
dc.subject.meshTime factorsen_US
dc.subject.meshTriazinesen_US
dc.subject.meshTriazolesen_US
dc.subject.meshUridineen_US
dc.subject.meshVentricular function, leften_US
dc.subject.meshVentricular pressureen_US
dc.subject.meshXanthinesen_US
dc.titleHypotensive effects of intravenously administered uridine and cytidine in conscious rats: Involvement of adenosine receptorsen_US
dc.typeArticleen_US
dc.identifier.wos000255583300016tr_TR
dc.identifier.scopus2-s2.0-41149118820tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-9496-1475tr_TR
dc.identifier.startpage125tr_TR
dc.identifier.endpage136tr_TR
dc.identifier.volume584tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalEuropean Journal of Pharmacologyen_US
dc.contributor.buuauthorYılmaz, Mustafa Sertaç-
dc.contributor.buuauthorCoskun, Cenk Nuri-
dc.contributor.buuauthorMutlu, Duygu-
dc.contributor.buuauthorSavci, Vahide-
dc.contributor.researcheridAAH-1571-2021tr_TR
dc.relation.collaborationYurt içitr_TR
dc.identifier.pubmed18313046tr_TR
dc.subject.wosPharmacology & pharmacyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.contributor.scopusid8895544100tr_TR
dc.contributor.scopusid23667159700tr_TR
dc.contributor.scopusid23668710500tr_TR
dc.contributor.scopusid6603687024tr_TR
dc.subject.scopusCiticoline; Neuroprotective Agents; Glycerylphosphorylcholineen_US
dc.subject.emtree3,7 dimethyl 1 propargylxanthineen_US
dc.subject.emtree4 [2 [7 amino 2 (2 furyl) 1,2,4 triazolo[2,3 a][1,3,5]triazin 5 ylamino]ethyl]phenolen_US
dc.subject.emtree8 (4 sulfophenyl)theophyllineen_US
dc.subject.emtree8 cyclopentyl 1,3 dipropylxanthineen_US
dc.subject.emtree8 phenyltheophyllineen_US
dc.subject.emtreeAdenosine A1 receptoren_US
dc.subject.emtreeAdenosine A1 receptor antagonisten_US
dc.subject.emtreeAdenosine A2 receptoren_US
dc.subject.emtreeAdenosine A2 receptor antagonisten_US
dc.subject.emtreeAdenosine receptor blocking agenten_US
dc.subject.emtreeCaffeineen_US
dc.subject.emtreeCytidineen_US
dc.subject.emtreeUridineen_US
dc.subject.emtreeAnimal experimenten_US
dc.subject.emtreeAnimal tissueen_US
dc.subject.emtreeAntihypertensive activityen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlood pressure regulationen_US
dc.subject.emtreeBradycardiaen_US
dc.subject.emtreeCardiovascular effecten_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug dose comparisonen_US
dc.subject.emtreeDrug inhibitionen_US
dc.subject.emtreeHeart rateen_US
dc.subject.emtreeIsolated hearten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreenonhumanNen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreePurine metabolismen_US
dc.subject.emtreeRaten_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.